Page last updated: 2024-12-05

2,2-dichloroacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2,2-Dichloroacetamide (DCA) is a small molecule that has been studied for its potential anticancer effects. It inhibits pyruvate dehydrogenase kinase (PDK), which leads to increased glucose oxidation and a decrease in aerobic glycolysis, a metabolic hallmark of cancer cells. DCA has shown some promising results in preclinical studies, but its use in humans is limited due to its toxicity and potential side effects. DCA is also known to be a potent inhibitor of the enzyme pyruvate dehydrogenase kinase, which is involved in the regulation of glucose metabolism. This inhibition can lead to increased levels of pyruvate, which is a substrate for the citric acid cycle, and may ultimately result in increased ATP production. DCA is synthesized by the reaction of dichloroacetic acid with ammonia. It is a colorless solid that is soluble in water, ethanol, and diethyl ether. The effects of DCA are complex and depend on the concentration and duration of exposure. DCA has been studied for its potential to treat a variety of diseases, including cancer, diabetes, and neurodegenerative disorders. However, it is important to note that these studies are still in their early stages and much more research is needed before DCA can be considered a safe and effective treatment for any of these conditions.'

Cross-References

ID SourceID
PubMed CID12694
CHEMBL ID156653
SCHEMBL ID44759
MeSH IDM0101701

Synonyms (41)

Synonym
2,2'-dichloroacetamide
4-02-00-00505 (beilstein handbook reference)
unii-i202lta03d
i202lta03d ,
acetamide, 2,2-dichloro-
nsc 402025
brn 1743236
einecs 211-674-2
ai3-60126
dichloroacetamide
acetamide, dichloro-
nsc-402025
wln: gngv1
2,2-dichloroacetamide
683-72-7
nsc402025
D0306
CHEMBL156653 ,
2,2-dichloro-acetamide
A836121
NCGC00248506-01
EN300-66582
NCGC00257604-01
tox21_200050
cas-683-72-7
dtxsid8021561 ,
dtxcid301561
BBL013005
STL163868
AKOS005715852
FT-0609209
FT-0626986
SCHEMBL44759
W-104675
STR00269
mfcd00008015
Q5272474
bdbm50226208
D89626
CS-0149993
SY049540

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic effects of herbicides are often incompletely selective and can harm crops."( Reductive transformations of dichloroacetamide safeners: effects of agrochemical co-formulants and iron oxide + manganese oxide binary-mineral systems.
Psoras, AW; Ricko, AN; Sivey, JD, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.10840.006038.004119,952.5996AID1159521
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.54800.000229.305416,493.5996AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency54.79990.001024.504861.6448AID743215
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alcohol dehydrogenase E chainEquus caballus (horse)Ki6,456.54000.14122.89278.7000AID33855
Alcohol dehydrogenase S chainEquus caballus (horse)Ki6,456.54000.14122.89278.7000AID33855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1691499Inhibition of human mEH at 50 uM using CMNGC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay relative to control2020European journal of medicinal chemistry, May-01, Volume: 193Development of potent inhibitors of the human microsomal epoxide hydrolase.
AID23467Partition coefficient (logP)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
AID33855Inhibitory activity against horse liver alcohol dehydrogenase (ADH)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (17.78)18.7374
1990's2 (4.44)18.2507
2000's2 (4.44)29.6817
2010's24 (53.33)24.3611
2020's9 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (97.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]